Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Uniqure N.V.. (5/1/19). "Press Release: Uniqure to Participate in Multiple Upcoming Industry Conferences". Lexington, MA & Amsterdam.

Organisations Organisation Uniqure N.V. (Nasdaq: QURE)
  Group Uniqure (Group)
  Organisation 2 Canaccord Genuity Corporation
  Group Canaccord Genuity (Group)
Products Product Canaccord Genuity Gene Therapy Manufacturing Summit 2019 Boston
  Product 2 gene therapy
Person Person McMillan, Scott (Uniqure –201908 COO RETIRED 8/19)

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in May:

2019 American Academy of Neurology (AAN) Annual Meeting, May 4 – 10, Philadelphia, PA.

> uniQure will deliver multiple data presentations at the meeting covering the Company’s advancements for its gene therapy candidates in Huntington’s disease and Spinocerebellar Ataxia Type 3.

Canaccord Genuity Gene Therapy Manufacturing Summit, May 9, Boston, MA.

> Scott McMillan, chief operating officer at uniQure, will be presenting on Thursday May 9th at 10:00 a.m. ET, followed by the AAV Manufacturing panel discussion at 10:30 a.m. ET.

Hemostasis & Thrombosis Research Society 2019 Scientific Symposium, May 9 - 11, New Orleans, LA.

> Adam Giermasz, M.D., Ph.D., investigator of the trial at UC Davis, CA, will present 26 weeks of follow-up data on the three patients in the AMT-061 Phase 2b study.

Title: A Single Infusion of AMT-061 (AAV5-Padua hFIX) is Safe and Effective in Adults
with Hemophilia B: Interim Results from Dose-Confirmation Phase 2b Trial (#44)
Session: Poster Session 1
Date & Time: Friday, May 10, 4:45 – 5:55 p.m. CT
Location: St. Charles Ballroom

Italian Association of Huntington’s Disease Roma 2019 Meeting, May 18, Rome, Italy.

> Astrid Valles-Sanchez, senior scientist at uniQure will be presenting “Development of a microRNA-based gene therapy for Huntington’s disease” on Saturday, May 18th at 10:30 a.m. CET.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and other severe genetic diseases.

uniQure Contacts

For Investors:

Maria E. Cantor
Direct: 339-970-7536

Eva M. Mulder
Direct: +31 20 240 6103

For Media:

Tom Malone
Direct: 339-970-7558

Record changed: 2019-05-21


Picture [iito] Made Without Love 650x80px

More documents for Uniqure (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top